TY - JOUR
T1 - Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese hispanic patients with non-alcoholic fatty liver disease
AU - Espino, Alberto
AU - Villagrán, Andrea
AU - Vollrath, Valeska
AU - Hanckes, Paulina
AU - Salas, Roberto
AU - Farah, Andrea
AU - Solís, Nancy
AU - Pizarro, Margarita
AU - Escalona, Alex
AU - Boza, Camilo
AU - Pérez, Gustavo
AU - Carrasco, Gonzalo
AU - Padilla, Oslando
AU - Miquel, Juan Francisco
AU - Nervi, Flavio
AU - Chavez-Tapia, Norberto C.
AU - Arab, Juan Pablo
AU - Álvarez-Lobos, Manuel
AU - Arrese, Marco
AU - Riquelme, Arnoldo
PY - 2011
Y1 - 2011
N2 - Background. The plasminogen activator inhibitor type-1 (PAI-1) has been implicated in the regulation of fibrinolysis and extracellular matrix components. The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and may modulate hepatic fibrogenesis. Aim. To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients. Material and methods. Case-control study of 50 obese patients undergoing bariatric surgery and 71 non-obese subjects matched by age and sex. Anthropometric and biochemical measurements were performed, including PAI-1 serum levels. Genomic DNA was obtained to assess the presence of 4G/5G polymorphism. Results. BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects. PAI-1 serum levels observed in obese patients were significantly lower (10.63 ± 4.82) compared to controls (14.26 ± 11.4; p < 0.05). No differences were observed in the PAI-1 4G/5G promoter genotypes frequencies (p = 0.12). No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 ± 4.35) compared to patients without liver fibrosis (10.61 ± 5.2; p = 0.985). PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6). Conclusions. Morbidly obese patients had significantly lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects. The frequency of 4G/5G genotypes in Chilean Hispanic healthy subjects was similar to that described in other populations. No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients.
AB - Background. The plasminogen activator inhibitor type-1 (PAI-1) has been implicated in the regulation of fibrinolysis and extracellular matrix components. The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and may modulate hepatic fibrogenesis. Aim. To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients. Material and methods. Case-control study of 50 obese patients undergoing bariatric surgery and 71 non-obese subjects matched by age and sex. Anthropometric and biochemical measurements were performed, including PAI-1 serum levels. Genomic DNA was obtained to assess the presence of 4G/5G polymorphism. Results. BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects. PAI-1 serum levels observed in obese patients were significantly lower (10.63 ± 4.82) compared to controls (14.26 ± 11.4; p < 0.05). No differences were observed in the PAI-1 4G/5G promoter genotypes frequencies (p = 0.12). No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 ± 4.35) compared to patients without liver fibrosis (10.61 ± 5.2; p = 0.985). PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6). Conclusions. Morbidly obese patients had significantly lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects. The frequency of 4G/5G genotypes in Chilean Hispanic healthy subjects was similar to that described in other populations. No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients.
KW - Liver fibrosis
KW - Non-alcoholic fatty liver disease
KW - Plasminogen activator inhibitor type 1
KW - Single nucleotide polymorphisms
KW - Steatosis
UR - http://www.scopus.com/inward/record.url?scp=80052775237&partnerID=8YFLogxK
U2 - 10.1016/s1665-2681(19)31518-2
DO - 10.1016/s1665-2681(19)31518-2
M3 - Article
C2 - 21911891
AN - SCOPUS:80052775237
SN - 1665-2681
VL - 10
SP - 493
EP - 501
JO - Annals of Hepatology
JF - Annals of Hepatology
IS - 4
ER -